BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC). Meeting Abstract

cited authors

  • Aggarwal, Rahul Raj; Costin, Dan; Zhang Jingsong; Karsh, Lawrence Ivan; Healey, Diane, I; Linch, Mark David; Adurthi, Sreenivas; Petrylak, Daniel Peter; O'Neill, Vince; Monk, Paul

Publication Date

  • February 20, 2021

webpage

published in

category

volume

  • 39

issue

  • 6